Thrivent Financial for Lutherans increased its stake in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 5.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,738 shares of the medical instruments supplier’s stock after purchasing an additional 685 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.07% of LeMaitre Vascular worth $342,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in LMAT. Sofos Investments Inc. acquired a new stake in shares of LeMaitre Vascular during the 4th quarter worth about $36,000. BNP Paribas Arbitrage SA lifted its stake in shares of LeMaitre Vascular by 78.3% during the first quarter. BNP Paribas Arbitrage SA now owns 6,538 shares of the medical instruments supplier’s stock valued at $163,000 after buying an additional 2,872 shares during the period. Oppenheimer Asset Management Inc. boosted its position in LeMaitre Vascular by 3,060.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 7,268 shares of the medical instruments supplier’s stock worth $182,000 after acquiring an additional 7,038 shares during the last quarter. SG Americas Securities LLC raised its holdings in LeMaitre Vascular by 129.6% in the 1st quarter. SG Americas Securities LLC now owns 7,364 shares of the medical instruments supplier’s stock valued at $184,000 after acquiring an additional 4,157 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of LeMaitre Vascular by 952.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,653 shares of the medical instruments supplier’s stock worth $203,000 after purchasing an additional 5,116 shares during the period. Institutional investors own 83.76% of the company’s stock.
Several research firms recently commented on LMAT. BidaskClub lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Lake Street Capital dropped their price target on shares of LeMaitre Vascular from $40.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Canaccord Genuity reiterated a “hold” rating and issued a $28.00 price target on shares of LeMaitre Vascular in a report on Tuesday, June 23rd. Barrington Research lowered their price objective on shares of LeMaitre Vascular from $38.00 to $32.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Finally, Sidoti cut their target price on LeMaitre Vascular from $38.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. LeMaitre Vascular currently has a consensus rating of “Hold” and a consensus target price of $31.00.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The firm had revenue of $30.55 million during the quarter, compared to the consensus estimate of $30.50 million. LeMaitre Vascular had a return on equity of 12.26% and a net margin of 14.75%. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.17 EPS. As a group, equities analysts forecast that LeMaitre Vascular Inc will post 0.42 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.095 dividend. The ex-dividend date of this dividend was Tuesday, May 19th. This represents a $0.38 dividend on an annualized basis and a dividend yield of 1.44%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 43.18%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
See Also: Holder of Record
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.